BICO (STO: BICO) introduced its second divestiture since Maria Forss took over as President and CEO in November 2023. Following the sale of Ginolis final yr, BICO has now entered an settlement to promote its Nanoscribe model to LAB14 for €26 million. The transaction is anticipated to shut within the fourth quarter of 2024, aligning with BICO’s up to date BICO 2.0 technique.
In response to Forss, the offloading is a part of BICO’s ongoing deal with the life sciences sector: “The divestment of Nanoscribe is a serious step in delivering on our up to date technique, which was launched throughout our Capital Markets Day in September. Nanoscribe is a worthwhile and steady enterprise; nevertheless, it has its largest potential and buyer base outdoors life science and is due to this fact concluded as non-core for BICO going ahead.”
As of November 21, 2024, BICO’s inventory closed at SEK 34.62 ($3.12). Over the previous 12 months, the inventory has declined by roughly 27%, reflecting the corporate’s restructuring efforts and market reactions to its strategic realignment.
BICO CEO Maria Forss. Picture courtesy of BICO.
Nanoscribe’s Profile and Market Impression
In Might 2021, underneath the management of then-CEO Erik Gatenholm, BICO (previously Cellink) acquired Nanoscribe to enhance BICO’s present product portfolio, together with boosting the model’s bioprinting capabilities. By combining Nanoscribe’s microstructural bioprinting expertise with BICO’s macrostructural bioprinting experience, the corporate aimed to create extra practical tissue architectures, together with vascularization and cell help constructions.
Nanoscribe’s expertise was anticipated to facilitate the event of consumables equivalent to implants, microneedles, microporous membranes, and instruments for omics functions, producing extra recurring income. The acquisition aligned with BICO’s broader bioconvergence technique. By incorporating Nanoscribe’s two-photon polymerization (2PP) expertise, BICO sought to remain aggressive within the miniaturization of gadgets throughout a variety of functions, significantly in life sciences.
Recognized for its groundbreaking 2PP expertise, Nanoscribe has been a pacesetter in high-resolution 3D printing functions. Its latest innovation, the Quantum X align, received the 2024 European Convention on Optical Communication (ECOC) Business Award within the “Chip-Scale Packaging/Optical Sub-Meeting” class.
This recognition highlights the model’s pioneering position in photonic integration, with improvements equivalent to Aligned 2-Photon Lithography (A2PL), a method for instantly 3D printing exactly aligned optical parts, and Two-Photon Grayscale Lithography (2GL), a proprietary expertise that makes use of dynamic voxel tuning to create detailed 3D microstructures with unprecedented velocity and accuracy.
In the meantime, the Quantum X align is significant for industries requiring exact and dependable optical connections. With lateral alignment accuracy right down to 100 nanometers and compatibility with supplies like silicon, indium phosphide, and glass, it’s used to 3D print parts equivalent to optical couplers and freeform micro-optics. It interconnects for photonic chips and optical fibers. These functions make it extremely valued in photonics manufacturing. Regardless of its success, the corporate’s major market lies outdoors life sciences—a key consider BICO’s choice to promote the model.
Quantum X align. Picture courtesy of Nanoscribe.
The transaction is anticipated to carry a revenue of about 10% in comparison with the worth recorded in BICO’s books on the finish of the third quarter of 2024. The precise quantity may change relying on change charges and when the deal is finalized. What’s extra, the cash from the sale can be used to repay a part of BICO’s long-term debt, which, as of the most recent obtainable knowledge, stands at roughly SEK1.4 billion ($126 million), together with loans and bonds owed to a number of collectors.
In response to BICO, Nanoscribe can be handled as a discontinued operation in BICO’s monetary studies from This fall 2024, with the ultimate monetary influence to be disclosed within the upcoming year-end report 2024, which can be reported on February 19, 2025.
BU Researcher Mustafa Çağatay Karakan makes use of Nanoscribe’s 3D printer to make scaffolds important for rising coronary heart tissues on the White Lab. Picture courtesy of 3DPrint.com.
Taking on the Nanoscribe reins can be LAB14, a German firm specializing in superior manufacturing options like nano- and microfabrication applied sciences. LAB14’s portfolio consists of corporations targeted on semiconductor manufacturing, microelectronics, and supplies science, suggesting that Nanoscribe will discover a extra aligned dwelling underneath its new possession. Nanoscribe can be becoming a member of eight sister corporations, together with Heidelberg Devices, which makes direct-write lithography programs; Osiris Worldwide, for gear utilized in semiconductor and microsystems expertise; and Nanosurf, which makes atomic pressure microscopes, amongst others.
Nanoscribe’s management, together with co-founders Martin Hermatschweiler (CEO) and Michael Thiel (CSO), is anticipated to proceed driving the corporate’s modern efforts, guaranteeing a easy transition and sustained progress underneath LAB14.
Nanoscribe founders Michael Thiel (left) and Martin Hermatschweiler (proper), with CFO Lars Tritschler (center). Picture courtesy of Nanoscribe
BICO’s Strategic Route
The sale of Nanoscribe follows the November 2023 divestiture of Finnish firm Ginolis, which was offered via a administration buyout for a symbolic €1. Ginolis had additionally been deemed a non-core asset on account of its post-pandemic market challenges. Each strikes present that BICO is dedicated to its new BICO 2.0 technique, concentrating sources on life sciences.
The corporate’s up to date technique emphasizes profitability and scalability within the life sciences sector. Throughout the second quarter of 2024, BICO reported steady gross sales and constructive EBITDA throughout all enterprise areas regardless of a unstable market surroundings. The proceeds from divestitures, coupled with operational changes, strengthen the corporate’s place in its core markets.
Cell culturing with Nanoscribe’s Quantum X bio. Picture courtesy of Nanoscribe.
Beneath the brand new technique, BICO now has eight subsidiaries, specializing in core areas inside life sciences. Nevertheless, this leaves room to surprise which firm is perhaps subsequent in its quest to streamline operations. Whereas a lot of its subsidiaries, equivalent to Cellink, Visikol, and MatTek, have clear and direct connections to life sciences, others could have a broader focus or serve industries outdoors BICO’s sharpened life sciences technique. This might affect the manager’s selections to refine its portfolio additional.
Trying Forward, the upcoming Q3 report, set for launch on November 26, 2024, will present extra perception into the corporate’s monetary efficiency and roadmap underneath Forss’s management. Within the meantime, for Nanoscribe, the transition to LAB14 may mark a possibility to increase its influence in markets outdoors life sciences, from photonics to optical communication.
Subscribe to Our E-mail E-newsletter
Keep up-to-date on all the most recent information from the 3D printing business and obtain data and presents from third celebration distributors.